XIONG Le, LIU An-wen, CHEN Zhi-yong. KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 8-13. DOI: 10.12019/j.issn.1671-5144.2022.01.003
|
Citation:
|
XIONG Le, LIU An-wen, CHEN Zhi-yong. KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 8-13. DOI: 10.12019/j.issn.1671-5144.2022.01.003
|
XIONG Le, LIU An-wen, CHEN Zhi-yong. KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 8-13. DOI: 10.12019/j.issn.1671-5144.2022.01.003
|
Citation:
|
XIONG Le, LIU An-wen, CHEN Zhi-yong. KEYNOTE-799: Pembrolizumab Plus Concurrent Chemoradiation in Unresectable, Locally Advanced, Stage Ⅲ Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2022, 22(1): 8-13. DOI: 10.12019/j.issn.1671-5144.2022.01.003
|
DownLoad: